NovoCure reported Q4 2025 net revenues of USD 174.4 million (up 8.0% year-over-year) and FY 2025 net revenues of USD 655.4 million (up 8.0%). Q4 gross margin was 76% (down from 79%), while Q4 R&D and clinical studies expenses rose to USD 60.9 million (up 19.0%) and sales and marketing expenses were USD 68.7 million (up 2.0%); general and administrative expenses fell to USD 43.0 million (down 41.0%). NovoCure posted a Q4 net loss of USD 24.5 million (loss per share USD 0.22) and Q4 adjusted EBITDA of USD -16.4 million, and ended 2025 with cash, cash equivalents and short-term investments of USD 447.7 million. Operationally, NovoCure reported 4,620 total active patients on Tumor Treating Fields therapy globally as of Dec. 31, 2025, including 4,464 active Optune Gio patients and 156 active Optune Lua patients; Q4 recognized revenue from Optune Lua was USD 3.5 million. The company highlighted February 2026 U.S. FDA approval of Optune Pax for locally advanced pancreatic cancer, CEO Frank Leonard’s appointment in December 2025, and a February 2026 update that CMS reinstated NovoCure’s U.S. billing privileges retroactive to Dec. 17, 2025 following an administrative re-validation issue. For 2026, NovoCure guided total net revenues of USD 675 million to USD 705 million and adjusted EBITDA of USD -20 million to USD 0, and outlined upcoming milestones including PANOVA-4 topline data in Q1 2026 and TRIDENT topline data in Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260226784598) on February 26, 2026, and is solely responsible for the information contained therein.